Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 12/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.40 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740171 | 1.00 | ROCK2 (0.42) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL12295015 | 1.00 | ROCK2 (0.42) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL1738777 | 1.00 | ROCK2 (0.42) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL12295017 | 1.00 | ROCK2 (0.42) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL1738655 | 1.00 | ROCK2 (0.42) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL1738670 | 0.91 | ROCK2 (0.40) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL1737753 | 0.91 | ROCK2 (0.40) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL1737725 | 0.91 | ROCK2 (0.40) | ROCK2BRD9BRD4BRPF1BRD7 | |
| SCHEMBL12327970 | 0.91 | ROCK2 (0.41) | ROCK2HTR2C | |
| SCHEMBL12327971 | 0.91 | ROCK2 (0.41) | ROCK2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012969-B2 | Radiopharmaceutical for positron emission tomography; imaging brain tissue; labeled serotonin type 1B (5HT1B) receptor ligands | GE HEALTHCARE LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20080206137-A1 | 11C-Labeled Benzyl-Lactam Compounds and Their Use as Imaging Agents | GE HEALTHCARE LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206137-A1 | 11C-Labeled Benzyl-Lactam Compounds and Their Use as Imaging Agents | TMEM14C, QPCT, PAICS | ROCK2 2938/4885BRD9 639/4885BRD4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.